Effects of metoprolol CR/XL on mortality and hospitalizations in patients with heart failure and history of hypertension

2002 ◽  
Vol 8 (1) ◽  
pp. 8-14 ◽  
Author(s):  
Johan Herlitz ◽  
John Wikstrand ◽  
Marty Denny ◽  
Paul Fenster ◽  
Thomas Heywood ◽  
...  
Keyword(s):  
Heart Failure ◽  
Patients With Heart Failure ◽  
History Of

scholarly journals The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure

2019 ◽  
Vol 109 (3) ◽  
pp. 331-338 ◽  
Author(s):  
Bernadet T. Santema ◽  
Michelle M. Y. Chan ◽  
Jasper Tromp ◽  
Martin Dokter ◽  
Haye H. van der Wal ◽  
...  
Keyword(s):  
Heart Failure ◽  
Atrial Fibrillation ◽  
Sinus Rhythm ◽  
Plasma Levels ◽  
Validation Cohort ◽  
Post Hoc Analysis ◽  
Patients With Heart Failure ◽  
History Of ◽  
Post Hoc ◽  
Multivariable Adjustment

Abstract Background In heart failure (HF), levels of NT-proBNP are influenced by the presence of concomitant atrial fibrillation (AF), making it difficult to distinguish between HF versus AF in patients with raised NT-proBNP. It is unknown whether levels of GDF-15 are also influenced by AF in patients with HF. In this study we compared the plasma levels of NT-proBNP versus GDF-15 in patients with HF in AF versus sinus rhythm (SR). Methods In a post hoc analysis of the index cohort of BIOSTAT-CHF (n = 2516), we studied patients with HF categorized into three groups: (1) AF at baseline (n = 733), (2) SR at baseline with a history of AF (n = 183), and (3) SR at baseline and no history of AF (n = 1025). The findings were validated in the validation cohort of BIOSTAT-CHF (n = 1738). Results Plasma NT-proBNP levels of patients who had AF at baseline were higher than those of patients in SR (both with and without a history of AF), even after multivariable adjustment (3417 [25th–75th percentile 1897–6486] versus 1788 [682–3870], adjusted p < 0.001, versus 2231 pg/mL [902–5270], adjusted p < 0.001). In contrast, after adjusting for clinical confounders, the levels of GDF-15 were comparable between the three groups (3179 [2062–5253] versus 2545 [1686–4337], adjusted p = 0.36, versus 2294 [1471–3855] pg/mL, adjusted p = 0.08). Similar patterns of both NT-proBNP and GDF-15 were found in the validation cohort. Conclusion These data show that in patients with HF, NT-proBNP is significantly influenced by underlying AF at time of measurement and not by previous episodes of AF, whereas the levels of GDF-15 are not influenced by the presence of AF. Therefore, GDF-15 might have additive value combined with NT-proBNP in the assessment of patients with HF and concomitant AF. Graphic abstract

scholarly journals Family History of Dilated Cardiomyopathy among Patients with Heart Failure from the HF-ACTION Genetic Ancillary Study

2013 ◽  
Vol 6 (3) ◽  
pp. 179-183 ◽  
Author(s):  
Laura Hudson ◽  
Ana Morales ◽  
Ana Clara Mauro ◽  
David Whellan ◽  
Kirkwood F. Adams ◽  
...  
Keyword(s):  
Heart Failure ◽  
Family History ◽  
Dilated Cardiomyopathy ◽  
Ancillary Study ◽  
Patients With Heart Failure ◽  
History Of

Is History of Depression a Predictor of In-Hospital Treatment and Early Post-Discharge Outcomes in Patients with Heart Failure? A Report from OPTIMIZE-HF

2007 ◽  
Vol 13 (6) ◽  
pp. S162-S163
Author(s):  
Nancy M. Albert ◽  
Gregg C. Fonarow ◽  
Christopher M. O'Connor ◽  
Wendy G. Stough ◽  
Eduardo Nunez ◽  
...  
Keyword(s):  
Heart Failure ◽  
Hospital Treatment ◽  
Post Discharge ◽  
Patients With Heart Failure ◽  
Discharge Outcomes ◽  
History Of ◽  
History Of Depression

scholarly journals 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development

2017 ◽  
Vol 234 (1) ◽  
pp. T125-T140 ◽  
Author(s):  
Peter Kolkhof ◽  
Lars Bärfacker
Keyword(s):  
Heart Failure ◽  
Chronic Kidney Disease ◽  
Clinical Trials ◽  
Kidney Disease ◽  
Research And Development ◽  
Mineralocorticoid Receptor ◽  
Clinical Use ◽  
Patients With Heart Failure ◽  
History Of

The cDNA of the mineralocorticoid receptor (MR) was cloned 30 years ago, in 1987. At that time, spirolactone, the first generation of synthetic steroid-based MR antagonists (MRAs), which was identified in preclinical in vivo models, had already been in clinical use for 30 years. Subsequent decades of research and development by Searle & Co., Ciba-Geigy, Roussel Uclaf and Schering AG toward identifying a second generation of much more specific steroidal MRAs were all based on the initial 17-spirolactone construct. The salient example is eplerenone, first described in 1987, coincidentally with the cloning of MR cDNA. Its launch on the market in 2003 paralleled intensive drug discovery programs for a new generation of non-steroidal MRAs. Now, 30 years after the cDNA cloning of MR and 60 years of clinical use of steroidal MRAs, novel non-steroidal MRAs such as apararenone, esaxerenone and finerenone are in late-stage clinical trials in patients with heart failure, chronic kidney disease (CKD), hypertension and liver disease. Finerenone has already been studied in over 2000 patients with heart failure plus chronic kidney disease and/or diabetes, and in patients with diabetic kidney disease, in five phase II clinical trials. Here, we reflect on the history of the various generations of MRAs and review characteristics of the most important steroidal and non-steroidal MRAs.

Inequitable distribution of implantable cardioverter defibrillators in Ontario

2007 ◽  
Vol 23 (3) ◽  
pp. 354-361 ◽  
Author(s):  
Jacob A. Udell ◽  
David N. Juurlink ◽  
Alexander Kopp ◽  
Douglas S. Lee ◽  
Jack V. Tu ◽  
...  
Keyword(s):  
Heart Failure ◽  
Fold Increase ◽  
Population Based ◽  
Implantable Cardioverter Defibrillators ◽  
Icd Implantation ◽  
Coronary Syndrome ◽  
Patients With Heart Failure ◽  
History Of ◽  
And Gender ◽  
Cardioverter Defibrillators

Objectives:Implantable cardioverter defibrillator (ICD) therapy reduces the risk of sudden death in patients with ischemic cardiomyopathy, but their novelty and cost may represent barriers to utilization. The objective of this study was to examine the influence of age, gender, place of residence, and socioeconomic status on rates of ICD implantation for the primary prevention of death.Methods:We conducted a population-based retrospective cohort study involving the entire province of Ontario, Canada. Patients were eligible if they had survived following hospitalization for heart failure from 1 January 1993, to 31 March 2004, and previously sustained an acute coronary syndrome within 5 years. Patients with an existing ICD or a documented history of cardiac arrest were excluded, as were patients who died in the hospital. Primary outcome was ICD implantation.Results:We identified 48,426 patients hospitalized for heart failure who survived to hospital discharge. Of these, 440 received an ICD, with a gradual 30-fold increase in implantation rates over the study period (.12–3.9 percent). ICD recipients were more likely to be men (odds ratio [OR] = 4.14; 95 percent confidence interval [CI], 3.24–5.30), younger than 75 years of age (OR = 3.19; 95 percent CI, 2.57–3.96), reside in a metropolitan area (OR = 1.42; 95 percent CI, 1.04–1.9), and live in a higher socioeconomic neighborhood (OR = 1.32; 95 percent CI, 1.08–1.61).Conclusions:Among patients with heart failure and a previous myocardial infarction, ICD use is increasing in Ontario. However, the application of this technology is characterized by major sociodemographic inequities. The causes and consequences of the pronounced age and gender discrepancies, in particular, warrant further investigation.

scholarly journals P974 Sacubitril/valsartan is well tolerated in patients with heart failure and a history of cancer

2020 ◽  
Vol 21 (Supplement_1) ◽  
Author(s):  
M K Frey ◽  
E Han ◽  
H Arfsten ◽  
N Pavo ◽  
M Huelsmann ◽  
...  
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Cancer Patients ◽  
Functional Class ◽  
Reduced Ejection Fraction ◽  
Non Hodgkin Lymphoma ◽  
Patients With Heart Failure ◽  
History Of ◽  
History Of Cancer

Abstract Introduction Sacubitril/valsartan has been shown to significantly reduce cardiovascular mortality and hospitalisations due to heart failure in patients with reduced ejection fraction when compared to enalapril. Until now, sacubitril/valsartan has not been evaluated in patients with a history of cancer, as these patients were excluded from the pivotal trial, PARADIGM-HF. The aim of the current study was to assess tolerability of sacubitril/valsartan in patients with a history of cancer. Methods We retrospectively enrolled all patients at our heart failure out-patient unit who fulfilled the indication criteria to receive sacubitril/valsartan and had a history of cancer. Fifteen patients receiving sacubitril/valsartan had a diagnosis of histologically confirmed cancer: 26.7% breast cancer (n = 4), 13.3% osteosarcoma (n = 2), 13.3% colorectal cancer (n = 2), 13.3% renal cell carcinoma (n = 2), 6.7% non-Hodgkin lymphoma (n = 1), 6.7% lung cancer (n = 1), 6.7% prostate cancer (n = 1), 6.7% bladder carcinoma and 6.7% myeoloproliferative syndrome (n = 1). Surgery due to cancer was performed in 80% of patients (n = 12), 26.7% previously received chemotherapy (n = 6) and 40% radiation therapy (n = 4). Results Sacubitril/valsartan was withdrawn in 2 patients (13.3%) because of dizziness and pruritus respectively. After a mean follow-up of 13 ±8 months, NYHA functional class improved significantly (mean -0.5, p = 0.001), ejection fraction as assassed by echocardiography increased (mean +6.8%, p = 0.018) and NT-proBNP was significantly decreased (mean -1552pg/ml, p = 0.026). There was no significant change in creatinine levels (+0.046 mg/dl, p = 0.564 ). Conclusions In this pilot study we were able to show that sacubitril/valsartan is generally well tolerated in patients with a history of cancer. Patients with cardiotoxicity induced heart failure can be treated and uptitrated with sacubitril/valsartan to usual dosages similarly as in other causes of heart failure. Larger studies are needed to confirm these findings in cancer patients with cardiotoxicity.

scholarly journals History of Atrial Fibrillation as a Risk Factor in Patients With Heart Failure and Preserved Ejection Fraction

2014 ◽  
Vol 7 (6) ◽  
pp. 960-966 ◽  
Author(s):  
Oludamilola W. Oluleye ◽  
Thomas S. Rector ◽  
Sithu Win ◽  
John J.V. McMurray ◽  
Michael R. Zile ◽  
...  
Keyword(s):  
Heart Failure ◽  
Atrial Fibrillation ◽  
Risk Factor ◽  
Ejection Fraction ◽  
Preserved Ejection Fraction ◽  
Patients With Heart Failure ◽  
History Of

scholarly journals Cardiac failure and pulmonary hypertension secondary to renal arteriovenous malformation: a case report

2021 ◽  
Vol 15 (1) ◽  
Author(s):  
Laura J. Albak ◽  
Ashish H. Shah ◽  
James W. Tam
Keyword(s):  
Heart Failure ◽  
Arteriovenous Malformation ◽  
Incidental Finding ◽  
Low Cardiac Output ◽  
Case Presentation ◽  
Output State ◽  
Patients With Heart Failure ◽  
Renal Arteriovenous Malformation ◽  
History Of ◽  
High Output

Abstract Background Heart failure is usually associated with a low-cardiac-output state; however, a minority of these patients are characterized by a high-output cardiac state, described as a cardiac index of > 4 L/minute/m2. Usually such circulation is associated with low systemic vascular resistance or arteriovenous malformation (AVM), resulting in depressurized circulation and a high-output cardiac state. Treating physicians should be cognizant of such pathology when investigating patients with heart failure. As an example, renal arteriovenous malformations are a rare vascular phenomena that are typically the result of iatrogenic, traumatic or congenital etiology. Generally, non-salient, most are detected as an incidental finding. Case presentation A 75-year-old Afro-Caribbean man with multiple comorbidities presented to the emergency department with a 6-month history of heart failure symptoms. Cardiac catheterization demonstrated a giant right renal AVM leading to a significant left-to-right, post-tricuspid shunt that was treated with transcatheter coiling. Conclusions We present this case to emphasize the significance of a detailed workup in a patient with heart failure symptoms.

scholarly journals Attitudes, beliefs and barriers for adherence to the hyposodic diet in patients with heart failure

2020 ◽  
Vol 41 ◽  
Author(s):  
Simone Maria Muniz da Silva Bezerra ◽  
Bianka Santos Lopes ◽  
Patrícia Ponciano Bomfim ◽  
Rebeka Maria de Oliveira Belo ◽  
Monique Oliveira do Nascimento ◽  
...  
Keyword(s):  
Heart Failure ◽  
Cross Sectional Study ◽  
Dietary Sodium ◽  
Professional Relationships ◽  
Attitudes And Beliefs ◽  
Cross Sectional ◽  
Improve Health Status ◽  
Patients With Heart Failure ◽  
History Of ◽  
Improve Health

ABSTRACT Objectives: To identify attitudes, beliefs and barriers to adherence to the hyposodic diet in patients with heart failure and associated factors. Methods: Cross-sectional study with 41 individuals. The Dietary Sodium Restriction Questionnaire was used. Fisher's test was applied for analysis. Results: Attitudes were based on family and professional relationships; in the beliefs, it was highlighted to believe in the diet to improve health. As barriers, insufficient efforts were found to change the diet and taste of low salt foods. It was associated with adherence among the components factors such as: income, perception of cardiac improvement with the diet, family history of renal and heart failure and family adherence to the diet. Conclusions: The identified attitudes and beliefs refer, respectively, to social relationships and trust in the diet to improve health status. The barriers were: insufficient effort to modify the diet and food palatability. Economic, family and clinical factors were associated with hyposodic adherence.

Sign in / Sign up

Export Citation Format

Share Document